These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 23901051)

  • 21. Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles.
    Locatelli F; Del Vecchio L; Violo L; Pontoriero G
    Expert Opin Drug Saf; 2014 May; 13(5):551-61. PubMed ID: 24702470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hyperphosphatemia and phosphate binders.
    Schucker JJ; Ward KE
    Am J Health Syst Pharm; 2005 Nov; 62(22):2355-61. PubMed ID: 16278327
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes associated with phosphorus binders in men with non-dialysis-dependent CKD.
    Kovesdy CP; Kuchmak O; Lu JL; Kalantar-Zadeh K
    Am J Kidney Dis; 2010 Nov; 56(5):842-51. PubMed ID: 20728255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral phosphate binders for the management of serum phosphate levels in dialysis patients.
    Mohammed I; Hutchison AJ
    J Ren Care; 2009 Mar; 35 Suppl 1():65-70. PubMed ID: 19222734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Off-label use of phosphate binders in non-dialysis-dependent CKD.
    Winkelmayer WC; Chertow GM
    Am J Kidney Dis; 2010 Nov; 56(5):813-6. PubMed ID: 20970022
    [No Abstract]   [Full Text] [Related]  

  • 26. The economic impact of improving phosphate binder therapy adherence and attainment of guideline phosphorus goals in hemodialysis patients: a Medicare cost-offset model.
    Ramakrishnan K; Braunhofer P; Newsome B; Lubeck D; Wang S; Deuson J; Claxton AJ
    Adv Ther; 2014 Dec; 31(12):1272-86. PubMed ID: 25479935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dietary phosphorus restriction in advanced chronic kidney disease: merits, challenges, and emerging strategies.
    Gutiérrez OM; Wolf M
    Semin Dial; 2010; 23(4):401-6. PubMed ID: 20557490
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Phosphate control in end stage renal disease: barriers and opportunities. Malnutrition: yes or not?].
    Di Iorio B; Di Micco L
    G Ital Nefrol; 2013; 30(6):. PubMed ID: 24402667
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phosphate binders in CKD: chalking out the differences.
    Rees L; Shroff RC
    Pediatr Nephrol; 2010 Mar; 25(3):385-94. PubMed ID: 19898877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Hyperphosphatemia in dialysis: which binder?].
    Alfieri C; Malberti F; Mazzaferro S; Gallieni M; Russo D; Messa P; Cozzolino M
    G Ital Nefrol; 2018 Sep; 35(5):. PubMed ID: 30234231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
    Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
    Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Newly development of phosphate binders in hyperphosphatemic patients with kidney dysfunction].
    Negi S; Yamanaka S; Koreeda D; Yashiro M; Shigematsu T
    Clin Calcium; 2012 Oct; 22(10):1557-66. PubMed ID: 23023637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Are calcium-based phosphate binders ever preferable in dialysis patients?
    Jain N; Reilly RF
    Semin Dial; 2014; 27(3):269-72. PubMed ID: 24620781
    [No Abstract]   [Full Text] [Related]  

  • 34. The challenge of controlling phosphorus in chronic kidney disease.
    Cannata-Andía JB; Martin KJ
    Nephrol Dial Transplant; 2016 Apr; 31(4):541-7. PubMed ID: 25770169
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia.
    Locatelli F; Cannata-Andía JB; Drüeke TB; Hörl WH; Fouque D; Heimburger O; Ritz E
    Nephrol Dial Transplant; 2002 May; 17(5):723-31. PubMed ID: 11981055
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study.
    Block GA; Hulbert-Shearon TE; Levin NW; Port FK
    Am J Kidney Dis; 1998 Apr; 31(4):607-17. PubMed ID: 9531176
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis: results of the CARE study.
    Qunibi WY; Nolan CR
    Kidney Int Suppl; 2004 Sep; (90):S33-8. PubMed ID: 15296505
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment options for hyperphosphatemia in feline CKD: what's out there?
    Kidder AC; Chew D
    J Feline Med Surg; 2009 Nov; 11(11):913-24. PubMed ID: 19857854
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of daily dialysis in the control of hyperphosphatemia.
    Achinger SG; Ayus JC
    Kidney Int Suppl; 2005 Jun; (95):S28-32. PubMed ID: 15882310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phosphate binders, cardiovascular calcifications and mortality: do we need another survival study with sevelamer?
    Negri AL
    J Nephrol; 2010; 23(6):653-7. PubMed ID: 20349415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.